...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith trial partners
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Pay, I will take a stab a valuation

Pfizer paid  14 Billion usd for Medivation in 2017 to lock up Xandi which was being approved , so I am going to say $1 Billion usd plus royalties is a very very conservative starting point for the potential of Zen 3694 that has a few years before being approved.  Dm stated a few times they can try with an earlier approval if the ORR is over 30%
we'll see

 

4 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply